^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tivantinib (ARQ 197)

    i
    Company:
    Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
    Drug class:
    c-MET inhibitor
    Related drugs:
    Apply
    Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (NCT01892527)
    Phase 2
    Armando Santoro, MD
    Completed
    Last update posted :
    09/09/2022
    Initiation :
    03/01/2013
    Primary completion :
    05/01/2016
    Completion :
    03/01/2017
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • tivantinib (ARQ 197)
    ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer (NCT01075048)
    Phase 1/2
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    01/26/2010
    Primary completion :
    10/12/2012
    Completion :
    02/20/2015
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • irinotecan • tivantinib (ARQ 197)
    Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin (NCT02049060)
    Phase 1/2
    Armando Santoro, MD
    Completed
    Last update posted :
    01/22/2021
    Initiation :
    01/01/2013
    Primary completion :
    05/01/2016
    Completion :
    12/01/2017
    MET • HGF
    |
    MET expression
    |
    carboplatin • pemetrexed • tivantinib (ARQ 197)
    Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma (NCT01447914)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    11/01/2011
    Primary completion :
    03/01/2014
    Completion :
    04/01/2014
    CD4
    |
    tivantinib (ARQ 197)
    Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (NCT01696955)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/19/2018
    Initiation :
    08/20/2012
    Primary completion :
    05/05/2017
    Completion :
    05/05/2017
    EGFR • MET
    |
    MET expression
    |
    Erbitux (cetuximab) • tivantinib (ARQ 197)
    Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT01395758)
    Phase 2
    ArQule, Inc. (a wholly owned subsidiary of Merc...
    Completed
    Last update posted :
    04/03/2018
    Initiation :
    07/01/2011
    Primary completion :
    08/01/2016
    Completion :
    08/01/2016
    KRAS • MET
    |
    KRAS mutation
    |
    erlotinib • gemcitabine • docetaxel • pemetrexed • tivantinib (ARQ 197)
    Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01749384)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/12/2017
    Initiation :
    12/06/2012
    Primary completion :
    05/24/2016
    Completion :
    05/24/2016
    STAT3
    |
    Avastin (bevacizumab) • tivantinib (ARQ 197)
    A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (NCT02029157)
    Phase 3
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    10/09/2017
    Initiation :
    01/01/2014
    Primary completion :
    08/01/2017
    Completion :
    08/01/2017
    MET
    |
    MET-H
    |
    sorafenib • tivantinib (ARQ 197)
    A Study of ARQ 197 in Combination With Erlotinib (NCT01251796)
    Phase 1
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    03/15/2017
    Initiation :
    12/01/2010
    Primary completion :
    11/01/2012
    Completion :
    11/01/2012
    EGFR
    |
    erlotinib • tivantinib (ARQ 197)
    A Study of ARQ 197 in Combination With Erlotinib (NCT01069757)
    Phase 1
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    03/15/2017
    Initiation :
    02/01/2010
    Primary completion :
    09/01/2011
    Completion :
    09/01/2011
    EGFR
    |
    erlotinib • tivantinib (ARQ 197)
    ARQ197 in Metastatic Triple-Negative Breast Cancer (NCT01542996)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    03/21/2016
    Initiation :
    04/01/2012
    Primary completion :
    08/01/2013
    HER-2 • PGR • MET
    |
    MET positive
    |
    tivantinib (ARQ 197)
    Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/21/2016
    Initiation :
    03/01/2012
    Primary completion :
    07/01/2013
    Completion :
    07/01/2013
    HER-2 • ER • PGR • MET
    |
    HER-2 negative • ER negative • MET expression • MET positive • PGR negative
    |
    tivantinib (ARQ 197)
    ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer (NCT01580735)
    Phase 2
    Kyowa Kirin Co., Ltd.
    Completed
    Last update posted :
    08/18/2015
    Initiation :
    05/01/2012
    Primary completion :
    04/01/2015
    Completion :
    04/01/2015
    EGFR
    |
    EGFR mutation
    |
    erlotinib • tivantinib (ARQ 197)
    Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT01725191)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/02/2015
    Initiation :
    10/01/2012
    Primary completion :
    05/01/2015
    Completion :
    05/01/2015
    AFP
    |
    tivantinib (ARQ 197)